CGON · CG Oncology, Inc.
$66.04
-1.35 (-2.00%)
At close · Oct 5
Return incl. dividend (before tax)
Market Cap
$6.24B
Shares
88.64M
Volume · Oct 5
113.5K
Avg daily vol (3M)
898.25K
Price & Indicators
20d MA
50d MA
200d MA
Earnings
Filing
Insider
Congress
Investor day
Close$67.38
Open$69.35
Day$66.61–69.73
52W close$37.37–80.68
Avg vol 30d932K
Short int11.3M · 12.7% float · 17.0d
Short vol19%
DataJan 2024–Oct 2026
Filing10-Q · Aug 6
Up next
filed Aug 6, 2026
Metrics snapshot
Useful current figures from the complete screener profile.
Revenue (TTM)
$6.23M
Trailing 12 months
Net income (TTM)
−$224.38M
Trailing 12 months
Revenue growth YoY
+254.7%
Year over year
Operating margin
-4,056.2%
Trailing 12 months
P / E (TTM)
—
Trailing earnings
FCF yield
-2.9%
TTM · current market cap
Return on invested capital
—
Trailing 12 months
Net cash
$1.03B
Latest balance sheet
Dividend yield
—
Trailing 12 months
Shares change YoY
+15.7%
Year over year · more shares
Price change (1Y)
+69.1%
Trailing year
Short interest
12.7%
Latest settlement · 17.0 days to cover
Equibles Rating
blended score · not investment adviceOverall
Sell
SellHoldBuy
Technical
Neutral
Momentum
Weak
Sentiment
Bullish
Fundamentals
Weak
Quant / Vol
Very High
Market backdrop
VIX 15.3 · calm
Equity put/call 0.58
Technical
price trend
50 / 200-day cross
No cross
Price vs 200-day avg
+5%
above
Price vs 50-day avg
−9%
below
RSI (14)
39
neutral
MACD trend
Negative
52-week position
69%
mid-range
Volume (OBV)
Confirms
volume backs price
Momentum
relative strength
1-month return
−9%
trailing
6-month return
0%
trailing
YTD return
+62%
this year
Relative strength
−13%
vs S&P · 6-mo
Sentiment
smart money
Trend (MA cross)
No cross
50d $74 › 200d $64 — 50d above 200d
Institutional flow
Accumulating
2 of 235 funds reported for Sep 30 · net +1 sh shares · +1 new
Insider flow
Flat
No net insider activity over 90 days
Short interest
Falling
12.70% of float · ▼ -1.2% MoM · 17.0 days cover
Volume signal
Reversal watch
High volume on a down day — possible exhaustion
Institution breadth
Multi-yr high
235 holders — near 2-yr high, broad support
Squeeze score
67
elevated · 0–100
Fundamentals
Revenue growth
+255%
Y/Y
EPS growth
−48%
Y/Y
Free cash flow
$-132.5M
Quant / Vol
risk profile
Volatility
57%
annualized · 1-yr
Max drawdown
−27%
past year
ATR
5.0%
of price · 14-day
Blended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.
Technicals
trend & momentum for long-term holders Neutral
50 / 200-day cross
No cross
Neutral
Price vs 200-day avg
+5%
Bullish
Price vs 50-day avg
−9%
Bearish
RSI (14)
39
Neutral
MACD trend
Negative
Bearish
52-week position
69%
Neutral
Volume (OBV)
Confirms
Neutral
Market signals — smart money & positioning
Bullish · 3 of 6
Trend (MA cross)
No cross
50d $74 › 200d $64 — 50d above 200d
Institutional flow
Accumulating
2 of 235 funds reported for Sep 30 · net +1 sh shares · +1 new
Insider flow
Flat
No net insider activity over 90 days
Short interest
Falling
12.70% of float · ▼ -1.2% MoM · 17.0 days cover
Volume signal
Reversal watch
High volume on a down day — possible exhaustion
Institution breadth
Multi-yr high
235 holders — near 2-yr high, broad support
Price context
position in its 52-week range
Range low $37
Now $67 · 69%
Range high $81
vs 200-day avg +5%
vs 50-day avg -9%
Illustrative technical + ownership context — a signal mix, not investment advice.
Key metrics
Earlier KPI extraction records exist, but do not meet the current evidence-completeness requirements. No current verified series is available. Earlier figures remain withheld until revalidated; this is not evidence that the company reports no KPIs.
Versus peers
Biotechnology — same industry group| Company | Mkt cap | YTD | Rev growth Y/Y | P/E | Short % shares |
|---|---|---|---|---|---|
|
CGON
this stock
CG Oncology, Inc.
|
$6.24B | +62.3% | +254.7% | — | 12.7% |
|
VRTX
Vertex Pharmaceuticals Inc / Ma
|
$133.37B | +11.3% | +46.2% | 30.7 | 1.9% |
|
REGN
Regeneron Pharmaceuticals, Inc.
|
$81.13B | -4.8% | +20.8% | 19.5 | 2.5% |
|
MRNA
Moderna, Inc.
|
$79.40B | +544.3% | +4.3% | — | 8.2% |
|
CSLLY
Csl Ltd
|
$61.25B | — | — | — | 0.0% |
Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding
At a glance
key data from every sectionOwnership
Short & Settlement
Financials
Filings
Earnings & Events
Performance
| 5D | 20D | 120D | MTD | YTD | |
|---|---|---|---|---|---|
| CGON | +0.3% | -9.4% | -0.5% | -5.0% | +62.3% |
| SPY | -0.2% | -0.5% | +12.2% | +0.9% | +12.9% |
| vs SPY | +0.6% | -8.9% | -12.7% | -5.9% | +49.4% |